World's Best Scientists 2026 revealed!
Véronique Diéras

Véronique Diéras

D-Index & Metrics

Medicine

D-Index
95
Citations
49750
World Ranking
9875
National Ranking
302

Véronique Diéras publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Véronique Diéras sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 549 publications — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Véronique Diéras D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Véronique Diéras sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Véronique Diéras is affiliated with the Institute Curie in France, focusing on oncology and breast cancer research. Their work spans the domains of medicine, with a particular emphasis on oncology, pulmonary and respiratory medicine, cancer research, genetics, and molecular biology.

Their research concentrates on multiple key topics including advanced breast cancer therapies, HER2/EGFR in cancer research, cancer treatment and pharmacology, breast cancer treatment studies, cancer immunotherapy and biomarkers, PARP inhibition in cancer therapy, and cancer genomics and diagnostics.

Frequent publication venues for their work include Annals of Oncology, Cancer Research, Journal of Clinical Oncology, European Journal of Cancer, and ESMO Open.

Coauthors who have regularly collaborated with Véronique Diéras include Hope S. Rugo, Javier Cortés, Delphine Loirat, Florence Dalenc, and Christelle Lévy.

Notable recent papers authored or coauthored by Véronique Diéras include:

  • Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial, 2020, The Lancet Oncology
  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer, 2021, New England Journal of Medicine
  • First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis, 2021, Annals of Oncology
  • Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial, 2023, Nature Medicine
  • Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study, 2021, JNCI Journal of the National Cancer Institute

Best Publications

  • Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

    Sunil Verma;David Miles;Luca Gianni;Ian E. Krop

  • Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

    Peter Schmid;Stephen Y Chui;Leisha A Emens

  • Palbociclib and Letrozole in Advanced Breast Cancer

    Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones

  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    F. Cardoso;A. Costa;E. Senkus;M. Aapro

  • RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

    Nicholas J. Robert;Véronique Diéras;John Glaspy;Adam M. Brufsky

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Aditya Bardia;Sara A Hurvitz;Sara M Tolaney;Delphine Loirat

  • Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

    Stephen Johnston;John Pippen;Xavier Pivot;Mikhail Lichinitser

  • Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study

    Javier Cortes;Joyce O'Shaughnessy;David Loesch;Joanne J.L. Blum

  • Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

    Peter Schmid;Hope S Rugo;Sylvia Adams;Andreas Schneeweiss

  • Lapatinib Plus Capecitabine in Patients With Previously Untreated Brain Metastases From HER2-positive Metastatic Breast Cancer (LANDSCAPE): A Single-Group Phase 2 Study

    Thomas Bachelot;Gilles Romieu;Mario Campone;Véronique Diéras

  • Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

    Nancy U Lin;Véronique Diéras;Devchand Paul;Dominique Lossignol

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

    Maura N. Dickler;Sara Tolaney;Hope S. Rugo;Javier Cortés

  • Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

    Véronique Diéras;David Miles;Sunil Verma;Mark Pegram

  • Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

    Joanne L. Blum;Véronique Dieras;Patricia Mucci Lo Russo;John Horton

  • A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays

    Elisabetta Marangoni;Anne Vincent-Salomon;Nathalie Auger;Armelle Degeorges

  • 進行性乳癌のためのESO-ESMO国際コンセンサスガイドライン第四版(ABC 4)

    F Cardoso;E Senkus;A Costa;E Papadopoulos

  • Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).

    Fabrice André;Fabrice André;Thomas Bachelot;Frederic Commo;Mario Campone

  • Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

    Martine Piccart-Gebhart;Eileen Holmes;Jośe Baselga;Evandro De Azambuja

  • Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

    J Maltzman;Marck Pegram;Saeed Sadeghi;Cristina Oliva

Frequent Co-Authors

Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Jean-Yves Pierga
Jean-Yves Pierga Institute Curie
Mario Campone
Mario Campone Grenoble Alpes University
Javier Cortes
Javier Cortes Vall d'Hebron Hospital Universitari
Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München
Karen A. Gelmon
Karen A. Gelmon University of British Columbia
Bernard Asselain
Bernard Asselain Institute Curie
Richard S. Finn
Richard S. Finn University of California, Los Angeles
Sherene Loi
Sherene Loi Peter MacCallum Cancer Centre
Anne Vincent-Salomon
Anne Vincent-Salomon Institute Curie

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're drawn to the field of medicine but considering alternative pathways beyond a traditional MD program, there are several respected online degree options to explore. Many students pursue healthcare administration as a leadership-focused path, and the top online mha programs that are cahme accredited offer flexible options with rigorous standards.

Registered nurses looking to advance their credentials may be interested in online rn to bsn no clinicals pathways, which are tailored for working professionals and eliminate the requirement of additional in-person clinicals. For those already holding a master’s degree, the demand for advanced nurse practitioners has led to the emergence of the quickest dnp program tracks, helping you earn a Doctor of Nursing Practice in less time.

Affordability is also a growing concern for many students. Exploring the cheapest dnp programs can help you find budget-friendly options without compromising on quality. Online healthcare degrees can open doors to diverse roles in patient care, education, administration, and research—helping you make a real impact in the medical field.

Best Scientists Citing Véronique Diéras

Trending Scientists

Recently Published Articles